Dietary linoleate supplementation modulates formyl-peptide receptor expression and functional responses of rat neutrophils.
We studied effects of dietary supplementation with the essential fatty acid (EFA) linoleic acid (LA) to see if neutrophil responses would be modulated. Neutrophils from rats maintained on a diet supplemented with EFA to 10% of the energy content--the high EFA (HEFA) group--showed a significantly higher LA concentration (but similar arachidonic acid content) compared with neutrophils from control rats maintained on a standard diet with 3% of the energy content as EFA. The HEFA group showed a significantly higher neutrophil oxidative metabolism compared with controls in response to N-formyl-methionyl-leucyl-phenylalanine (FMLP), but this response was equal to control values when stimulated by ionophore A23187, sodium fluoride, or phorbol myristate acetate. Similarly, FMLP conferred a more pronounced increase of intracellular Ca2+ in HEFA neutrophils, whereas this response to ionomycin was equal to that in controls. In contrast, HEFA rat neutrophil migration was decreased to 71% of the value in controls in response to FMLP. Similar results were observed for aggregation responses. On A23187 stimulation, HEFA and control neutrophils generated equal amounts of leukotriene B4 and other 5-lipoxygenase products as well as thromboxane B2 and 6-keto-prostaglandin F1 alpha. However, assessment of binding of FMLP labeled with tritium revealed an increase of the low affinity state of the FMLP receptor population. Thus an increased intake of one unsaturated fatty acid, LA, leading to its accumulation in neutrophils, conferred alterations in formyl-peptide-elicited responses, not associated with the formation of the assessed arachidonate-derived mediators, but most likely through the observed modulation of FMLP receptor subpopulations.
Gyllenhammar
H
H
Department of Medicine 3, Karolinska Institute, Södersjukhuset, Stockholm, Sweden.
Hafström
I
I
Borgeat
P
P
Ringertz
B
B
Becker
W
W
Svensson
J
J
Palmblad
J
J
D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D000818:Animals; D001094:Arachidonate 5-Lipoxygenase / Q000378:metabolism; D000001:Calcimycin / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D004041:Dietary Fats / Q000494:pharmacology*; D015759:Ionomycin / Q000494:pharmacology; D007975:Leukotriene B4 / Q000378:metabolism; D019787:Linoleic Acid; D008041:Linoleic Acids / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D008297:Male; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000378:metabolism / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism*; D010084:Oxidation-Reduction; D051381:Rats; D011919:Rats, Inbred Strains; D044042:Receptors, Formyl Peptide; D011971:Receptors, Immunologic / Q000378:metabolism*; D012969:Sodium Fluoride / Q000494:pharmacology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D013929:Thromboxane B2 / Q000378:metabolism
D004041:Dietary Fats; D008041:Linoleic Acids; D044042:Receptors, Formyl Peptide; D011971:Receptors, Immunologic; D007975:Leukotriene B4; D000001:Calcimycin; D013929:Thromboxane B2; D015759:Ionomycin; D015121:6-Ketoprostaglandin F1 alpha; D009240:N-Formylmethionine Leucyl-Phenylalanine; D012969:Sodium Fluoride; D019787:Linoleic Acid; D001094:Arachidonate 5-Lipoxygenase; D013755:Tetradecanoylphorbol Acetate; D002118:Calcium